SOCS3 and Alzheimer disease: This data is particularly relevant because recent literature indicates that SOCS3, a well-known negative modulator of insulin signaling and immunoregulator, is increased in the brains of individuals with AD, suggesting that SOCS3 may regulate the central insulin signaling pathways that are implicated in neurodegeneration in AD [35].